Brought to you by 
Santaris Pharma brings in $12mm through sale of convertible bonds
28 Jun 2012
Executive Summary
Santaris Pharma AS has raised DKK70mm ($12mm) through the two-tranche sale of convertible bonds to current shareholders Sunstone Capital, Novo, Gilde Healthcare, Forbion Capital Partners, LD, Global Life Science Venture, Seventures, and company management. The proceeds will be used to continue development of Phase II Miravirsen for hepatitis C and to work on the company's Locked Nucleic Acid (LNA) platform, which helps identify drug candidates for infectious diseases, inflammation, cardiometabolic conditions, cancer, and rare genetic disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Santaris Pharma brings in $12mm through sale of convertible bonds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice